Aptevo Therapeutics Inc (APVO) concluded trading on Thursday at a closing price of $5.63, with 6.46 million shares of worth about $36.34 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -80.52% during that period and on December 12, 2024 the price saw a loss of about -43.76%. Currently the company’s common shares owned by public are about 0.50M shares, out of which, 0.50M shares are available for trading.
Stock saw a price change of -43.59% in past 5 days and over the past one month there was a price change of -44.63%. Year-to-date (YTD), APVO shares are showing a performance of -98.09% which decreased to -98.14% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.11 but also hit the highest price of $399.60 during that period. The average intraday trading volume for Aptevo Therapeutics Inc shares is 199.89K. The stock is currently trading -41.85% below its 20-day simple moving average (SMA20), while that difference is down -36.79% for SMA50 and it goes to -85.83% lower than SMA200.
Aptevo Therapeutics Inc (NASDAQ: APVO) currently have 0.50M outstanding shares and institutions hold larger chunk of about 6.93% of that.
The stock has a current market capitalization of $2.82M and its 3Y-monthly beta is at 5.01. It has posted earnings per share of -$941.56 in the same period. It has Quick Ratio of 1.70 while making debt-to-equity ratio of 1.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APVO, volatility over the week remained 45.95% while standing at 24.68% over the month.
Stock’s fiscal year EPS is expected to drop by -81.72% while it is estimated to increase by 62.82% in next year.
Coverage by Piper Jaffray stated Aptevo Therapeutics Inc (APVO) stock as an Overweight in their note to investors on October 05, 2017, suggesting a price target of $6 for the stock.